Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bausch Health Companies Inc.BHC · Entity 4363 | EVP and CFO | March 08, 2021 | March 11, 2021 |
| Elanco Animal Health IncELAN · Entity 3457 | Director | August 07, 2026 | August 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bausch Health Companies Inc.
Report date March 08, 2021 · Filed March 11, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares, No Par ValueSEC Table I · non-derivative | Direct | 386,618 |
Ending reported balance
After 2021-03-10 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2021-03-08 · Exercise / conversion · Acquired 49,324 · Balance 395,619 F1: Reflects common shares, no par value ("Common Shares") of Bausch Health Companies Inc. (the "Company") issued to the reporting person following the vesting of, and certification of performance metrics relating to, performance-based Restricted Share Units ("PSUs") granted to the reporting person on March 7, 2018. F2: Each PSU converts into Common Shares on a one-for-one basis Row 2 · 2021-03-08 · Grant · Acquired 50,518 · Balance 446,137 F1: Reflects common shares, no par value ("Common Shares") of Bausch Health Companies Inc. (the "Company") issued to the reporting person following the vesting of, and certification of performance metrics relating to, performance-based Restricted Share Units ("PSUs") granted to the reporting person on March 7, 2018. Row 3 · 2021-03-10 · Tax withholding · Disposed 59,519 · Balance 386,618 F3: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of PSUs and RSUs. |
| Restricted Share UnitsSEC Table II · derivative / convertible security · Expires 2021-03-07 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-03-08 · Exercise / conversion · Disposed 49,324 · Balance 0 F2: Each PSU converts into Common Shares on a one-for-one basis F4: The PSUs granted to the reporting person on March 7, 2018 were distributed on March 10, 2021 following certification of the achievement of certain performance metrics. F5: This PSU award was previously reported on a Form 4 filed on March 9, 2018 with the maximum potential award amount of 79,556 shares. Any portion of the award not vested as of the transaction date was cancelled as of that date. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects common shares, no par value ("Common Shares") of Bausch Health Companies Inc. (the "Company") issued to the reporting person following the vesting of, and certification of performance metrics relating to, performance-based Restricted Share Units ("PSUs") granted to the reporting person on March 7, 2018.
F2: Each PSU converts into Common Shares on a one-for-one basis
F3: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of PSUs and RSUs.
F4: The PSUs granted to the reporting person on March 7, 2018 were distributed on March 10, 2021 following certification of the achievement of certain performance metrics.
F5: This PSU award was previously reported on a Form 4 filed on March 9, 2018 with the maximum potential award amount of 79,556 shares. Any portion of the award not vested as of the transaction date was cancelled as of that date.
Elanco Animal Health Inc
Report date August 07, 2026 · Filed August 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 111,687 |
Reported balance
After 2026-08-07 transaction · row 1
1 source rowRow 1 · 2026-08-07 · Purchase · Acquired 10,000 · Balance 111,687 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 07, 2026 Filed Aug 10, 2026 20:13 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | PurchaseCommon Stock | 10,000 | $23.69 | $236,850.00 |
DisclosureSEC source: 0001374175-26-000005 · form4-08102026_080800.xml · nonDerivative · entry 1 Herendeen Paul · CIK 0001374175 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,687 Read SEC document |
| May 21, 2026 Filed May 26, 2026 20:46 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantCommon Stock | 12,196 | $0.00 | $0.00 |
DisclosureSEC source: 0001374175-26-000002 · form4-05262026_080505.xml · nonDerivative · entry 2 Herendeen Paul · CIK 0001374175 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,687 F2 · shares: Grant of restricted stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors. Read SEC document |
| May 21, 2026 Filed May 26, 2026 20:46 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantCommon Stock | 4,678 | $0.00 | $0.00 |
DisclosureSEC source: 0001374175-26-000002 · form4-05262026_080505.xml · nonDerivative · entry 1 Herendeen Paul · CIK 0001374175 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,491 F1 · shares: Grant of deferred stock units as a pro-rated annual equity award to each of the non-employee members of the Issuer's Board of Directors. Read SEC document |
| November 28, 2025 Filed Dec 2, 2025 22:01 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantCommon Stock | 10,314 | $0.00 | $0.00 |
DisclosureSEC source: 0001374175-25-000005 · form4-12022025_101236.xml · nonDerivative · entry 1 Herendeen Paul · CIK 0001374175 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,813 F1 · price: Grant of deferred stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors. Read SEC document |
| November 29, 2024 Filed Dec 3, 2024 22:15 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantCommon Stock | 18,169 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-028157 · form4-12032024_101202.xml · nonDerivative · entry 1 Herendeen Paul · CIK 0001374175 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,499 F1 · price: Grant of deferred stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors. Read SEC document |
| November 30, 2023 Filed Dec 4, 2023 22:33 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantCommon Stock | 20,374 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-015781 · form4-12042023_101245.xml · nonDerivative · entry 1 Herendeen Paul · CIK 0001374175 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,330 F1 · price: Grant of deferred stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors. Read SEC document |
| November 30, 2022 Filed Dec 2, 2022 22:12 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantCommon Stock | 18,649 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-011981 · form4-12022022_101213.xml · nonDerivative · entry 1 Herendeen Paul · CIK 0001374175 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,956 F1 · price: Grant of deferred stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors. Read SEC document |
| September 09, 2022 Filed Sep 9, 2022 20:29 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | PurchaseCommon Stock | 10,000 | $15.03 | $150,250.00 |
DisclosureSEC source: 0001415889-22-009495 · form4-09092022_010955.xml · nonDerivative · entry 1 Herendeen Paul · CIK 0001374175 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,307 Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 22:07 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantCommon Stock | 7,307 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-010521 · edgar.xml · nonDerivative · entry 1 Herendeen Paul · CIK 0001374175 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,307 F1 · price: Grant of deferred stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors. Read SEC document |
| March 10, 2021 Filed Mar 11, 2021 01:59 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Shares, No Par Value | 59,519 | $32.97 | $1,962,341.43 |
DisclosureSEC source: 0001127602-21-010166 · form4.xml · nonDerivative · entry 3 Herendeen Paul · CIK 0001374175 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 386,618 F3 · shares: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of PSUs and RSUs. Read SEC document |
| March 08, 2021 Filed Mar 11, 2021 01:59 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Exercise / conversionRestricted Share Units · Derivative | 49,324 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-010166 · form4.xml · derivative · entry 4 Herendeen Paul · CIK 0001374175 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 49,324 shares Expires 2021-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each PSU converts into Common Shares on a one-for-one basis F2 · price: Each PSU converts into Common Shares on a one-for-one basis F4 · derivative.exercise_date: The PSUs granted to the reporting person on March 7, 2018 were distributed on March 10, 2021 following certification of the achievement of certain performance metrics. F4 · derivative.expiration_date: The PSUs granted to the reporting person on March 7, 2018 were distributed on March 10, 2021 following certification of the achievement of certain performance metrics. F5 · balance_after: This PSU award was previously reported on a Form 4 filed on March 9, 2018 with the maximum potential award amount of 79,556 shares. Any portion of the award not vested as of the transaction date was cancelled as of that date. Read SEC document |
| March 08, 2021 Filed Mar 11, 2021 01:59 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantCommon Shares, No Par Value | 50,518 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-010166 · form4.xml · nonDerivative · entry 2 Herendeen Paul · CIK 0001374175 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 446,137 F1 · shares: Reflects common shares, no par value ("Common Shares") of Bausch Health Companies Inc. (the "Company") issued to the reporting person following the vesting of, and certification of performance metrics relating to, performance-based Restricted Share Units ("PSUs") granted to the reporting person on March 7, 2018. Read SEC document |
| March 08, 2021 Filed Mar 11, 2021 01:59 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Exercise / conversionCommon Shares, No Par Value | 49,324 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-010166 · form4.xml · nonDerivative · entry 1 Herendeen Paul · CIK 0001374175 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 395,619 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects common shares, no par value ("Common Shares") of Bausch Health Companies Inc. (the "Company") issued to the reporting person following the vesting of, and certification of performance metrics relating to, performance-based Restricted Share Units ("PSUs") granted to the reporting person on March 7, 2018. F2 · price: Each PSU converts into Common Shares on a one-for-one basis Read SEC document |
| March 03, 2021 Filed Mar 5, 2021 22:58 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantNon-qualified Stock Options (right To Purchase) · Derivative | 91,684 | $0.00 Strike: $32.56 | $0.00 |
DisclosureSEC source: 0001127602-21-009566 · form4.xml · derivative · entry 2 Herendeen Paul · CIK 0001374175 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,684 Underlying: Common Shares, No Par Value · 91,684 shares Expires 2031-03-03 F2 · derivative.exercise_date: The options vest in equal installments on each of the first three anniversaries of the date of grant. Read SEC document |
| March 03, 2021 Filed Mar 5, 2021 22:58 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantCommon Shares, No Par Value | 63,439 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-009566 · form4.xml · nonDerivative · entry 1 Herendeen Paul · CIK 0001374175 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 346,295 F1 · shares: Represents the award of restricted share units ("RSUs") which will vest one-third on each of the first three anniversaries following the date of grant, subject to the reporting person's continued service. Vested RSUs are settled in common shares, no par value, of Bausch Health Companies Inc. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:44 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Shares, No Par Value | 15,755 | $31.42 | $495,022.10 |
DisclosureSEC source: 0001127602-21-009199 · form4.xml · nonDerivative · entry 1 Herendeen Paul · CIK 0001374175 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,856 F1 · shares: This number represents common shares, no par value, of the Issuer withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 20:06 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Shares, No Par Value | 1,642 | $15.91 | $26,124.22 |
DisclosureSEC source: 0001127602-20-025184 · form4.xml · nonDerivative · entry 1 Herendeen Paul · CIK 0001374175 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,611 F1 · shares: This number represents common shares, no par value, of the Issuer withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| March 09, 2020 Filed Mar 12, 2020 01:01 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Shares, No Par Value | 9,328 | $20.96 | $195,514.88 |
DisclosureSEC source: 0001127602-20-010329 · form4.xml · nonDerivative · entry 1 Herendeen Paul · CIK 0001374175 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,253 F1 · shares: This number represents common shares, no par value, of the Issuer withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:24 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Shares, No Par Value | 7,167 | $24.44 | $175,161.48 |
DisclosureSEC source: 0001127602-20-009137 · form4.xml · nonDerivative · entry 1 Herendeen Paul · CIK 0001374175 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,581 F1 · shares: This number represents Common Shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 00:26 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantNon-qualified Stock Options (right To Purchase) · Derivative | 159,192 | $0.00 Strike: $24.77 | $0.00 |
DisclosureSEC source: 0001127602-20-008440 · form4.xml · derivative · entry 2 Herendeen Paul · CIK 0001374175 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,192 Underlying: Common Shares, No Par Value · 159,192 shares Expires 2030-02-26 F2 · derivative.exercise_date: The options vest in equal installments on each of the first three anniversaries of the date of grant. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 00:26 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantCommon Shares, No Par Value | 63,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-008440 · form4.xml · nonDerivative · entry 1 Herendeen Paul · CIK 0001374175 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,748 F1 · shares: Represents the award of restricted share units ("RSUs") which will vest one-third on each of the first three anniversaries following the date of grant, subject to the reporting person's continued service. Vested RSUs are settled in common shares, no par value ("Common Shares"), of Bausch Health Companies Inc. ("Bausch Health"). Read SEC document |
| September 16, 2019 Filed Sep 18, 2019 21:05 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Stock, No Par Value | 1,642 | $23.24 | $38,160.08 |
DisclosureSEC source: 0001127602-19-028754 · form4.xml · nonDerivative · entry 1 Herendeen Paul · CIK 0001374175 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,718 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| August 23, 2019 Filed Aug 27, 2019 20:07 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Stock, No Par Value | 24,625 | $22.40 | $551,600.00 |
DisclosureSEC source: 0001127602-19-027449 · form4.xml · nonDerivative · entry 1 Herendeen Paul · CIK 0001374175 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,360 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 20:31 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Stock, No Par Value | 9,796 | $23.56 | $230,793.76 |
DisclosureSEC source: 0001127602-19-011040 · form4.xml · nonDerivative · entry 1 Herendeen Paul · CIK 0001374175 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,985 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 22:09 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantNon-qualified Stock Options (right To Purchase) · Derivative | 124,002 | $0.00 Strike: $23.16 | $0.00 |
DisclosureSEC source: 0001127602-19-009246 · form4.xml · derivative · entry 2 Herendeen Paul · CIK 0001374175 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,002 Underlying: Common Shares, No Par Value · 124,002 shares Expires 2029-02-27 F2 · derivative.exercise_date: The options vest in equal installments on each of the first three anniversaries of the date of grant. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 22:09 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantCommon Stock, No Par Value | 62,915 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-009246 · form4.xml · nonDerivative · entry 1 Herendeen Paul · CIK 0001374175 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,781 F1 · shares: Represents the award of restricted share units ("RSUs") which will vest one-third on each of the first three anniversaries following the date of grant, subject to the reporting person's continued service. Vested RSUs are settled in common shares, no par value ("Common Shares"), of Bausch Health Companies Inc. ("Bausch Health"). Read SEC document |
| September 14, 2018 Filed Sep 17, 2018 18:58 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | GrantCommon Stock, No Par Value | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-027736 · form4.xml · nonDerivative · entry 2 Herendeen Paul · CIK 0001374175 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,866 F2 · shares: Represents matching Restricted Share Units ("MRSUs") granted to the Reporting Person in connection with the open market purchase of Common Shares of the Issuer reported on Table I (the "Purchased Shares"), pursuant to the Issuer's Matching Share Program. One-third of the MRSUs will vest on each of the first, second, and third anniversaries following the date of grant ("MRSU Grant Date"), subject to the Reporting Person's continued service (except in limited circumstances). Read SEC document |
| September 14, 2018 Filed Sep 17, 2018 18:58 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | PurchaseCommon Stock, No Par Value | 10,000 | $22.61 | $226,100.00 |
DisclosureSEC source: 0001127602-18-027736 · form4.xml · nonDerivative · entry 1 Herendeen Paul · CIK 0001374175 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,866 F1 · price: The price in Column 4 is a weighted average price. The prices actually paid in this transaction are within the range of $22.59 to $22.63 per share. Read SEC document |
| August 23, 2018 Filed Aug 27, 2018 23:32 UTC | Bausch Health Companies Inc. BHC · Entity 4363 | Tax withholdingCommon Stock, No Par Value | 24,626 | $22.37 | $550,883.62 |
DisclosureSEC source: 0001127602-18-026327 · form4.xml · nonDerivative · entry 1 Herendeen Paul · CIK 0001374175 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,866 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| March 13, 2018 Filed Mar 13, 2018 20:43 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | PurchaseCommon Stock, No Par Value | 15,000 | $16.10 | $241,470.00 |
DisclosureSEC source: 0001127602-18-011394 · form4.xml · nonDerivative · entry 1 Herendeen Paul · CIK 0001374175 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,492 F1 · price: The price in Column 4 is a weighted average price. The prices actually paid in this transaction range from $16.09 to $16.10 per Common Share. F2 · price: The reporting person has provided to the issuer, and the issuer will provide to any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, information regarding the number of shares purchased at each price within the range reported above. Read SEC document |
| March 07, 2018 Filed Mar 10, 2018 01:52 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | GrantRestricted Share Units · Derivative | 79,556 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-011036 · form4.xml · derivative · entry 3 Herendeen Paul · CIK 0001374175 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,556 Underlying: Common Stock · 79,556 shares Expires 2021-03-07 F3 · derivative.exercise_price: Represents a grant of performance-based RSUs. The target number of performance-based RSUs granted to the reporting person was 39,778 and the maximum number that can be distributed is 79,556. The performance-based RSUs shall vest and be distributed between 0-200% of target based on Valeant's Total Shareholder Return ("TSR") as measured for the 20 trading days preceding the TSR Measurement Date ("Measurement Date") which is the third anniversary of the grant date (March 7, 2021). If Valeant's TSR for the period between the grant date and the Measurement Date is below the 50th percentile ranking of the TSR for the applicable peer group based on the 20 trading days preceding the Measurement Date, the reporting person will receive no more than the number of Common Shares equal to the target number of performance-based RSUs subject to the award. F3 · derivative.exercise_date: Represents a grant of performance-based RSUs. The target number of performance-based RSUs granted to the reporting person was 39,778 and the maximum number that can be distributed is 79,556. The performance-based RSUs shall vest and be distributed between 0-200% of target based on Valeant's Total Shareholder Return ("TSR") as measured for the 20 trading days preceding the TSR Measurement Date ("Measurement Date") which is the third anniversary of the grant date (March 7, 2021). If Valeant's TSR for the period between the grant date and the Measurement Date is below the 50th percentile ranking of the TSR for the applicable peer group based on the 20 trading days preceding the Measurement Date, the reporting person will receive no more than the number of Common Shares equal to the target number of performance-based RSUs subject to the award. Read SEC document |
| March 07, 2018 Filed Mar 10, 2018 01:52 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | GrantNon-qualified Stock Options (right To Purchase) · Derivative | 177,482 | $0.00 Strike: $15.32 | $0.00 |
DisclosureSEC source: 0001127602-18-011036 · form4.xml · derivative · entry 2 Herendeen Paul · CIK 0001374175 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,482 Underlying: Common Shares, No Par Value · 177,482 shares Expires 2028-03-07 F2 · derivative.exercise_date: The options vest in equal installments on each of the first three anniversaries of the date of grant. Read SEC document |
| March 07, 2018 Filed Mar 10, 2018 01:52 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | GrantCommon Stock, No Par Value | 59,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-011036 · form4.xml · nonDerivative · entry 1 Herendeen Paul · CIK 0001374175 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,492 F1 · shares: Represents the award of restricted share units ("RSUs") which will vest one-third on each of the first three anniversaries following the date of grant, subject to the reporting person's continued service. Vested RSUs are settled in common shares, no par value ("Common Shares"), of Valeant Pharmaceuticals International, Inc. ("Valeant"). Read SEC document |
| August 23, 2017 Filed Aug 25, 2017 20:30 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | Tax withholdingCommon Stock, No Par Value | 17,175 | $14.14 | $242,854.50 |
DisclosureSEC source: 0001127602-17-026502 · form4.xml · nonDerivative · entry 1 Herendeen Paul · CIK 0001374175 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,825 F1 · shares: This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Restricted Share Units. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 21:04 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | PurchaseCommon Stock, no par value | 24,000 | $10.72 | $257,280.00 |
DisclosureSEC source: 0000885590-17-000017 · primary_doc.xml · nonDerivative · entry 1 Herendeen Paul · CIK 0001374175 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,000 F1 · shares: Represents volume-weighted average price of purchases of 24,000 shares of common stock (Shares) of Valeant Pharmaceuticals International, Inc. (the Company) at prices ranging from $10.60 to $10.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of Shares purchased by the reporting person at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.